AU2014306451B2 - Substituted hydroxamic acid compounds - Google Patents

Substituted hydroxamic acid compounds Download PDF

Info

Publication number
AU2014306451B2
AU2014306451B2 AU2014306451A AU2014306451A AU2014306451B2 AU 2014306451 B2 AU2014306451 B2 AU 2014306451B2 AU 2014306451 A AU2014306451 A AU 2014306451A AU 2014306451 A AU2014306451 A AU 2014306451A AU 2014306451 B2 AU2014306451 B2 AU 2014306451B2
Authority
AU
Australia
Prior art keywords
alkyl
alkoxy
optionally substituted
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014306451A
Other languages
English (en)
Other versions
AU2014306451A1 (en
Inventor
Robert A. Nicholas
Eric J. Toone
Pei Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Duke University
Original Assignee
University of North Carolina at Chapel Hill
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Duke University filed Critical University of North Carolina at Chapel Hill
Publication of AU2014306451A1 publication Critical patent/AU2014306451A1/en
Assigned to DUKE UNIVERSITY, UNIVERSITY OF NORTH CAROLINA reassignment DUKE UNIVERSITY Amend patent request/document other than specification (104) Assignors: DUKE UNIVERSITY
Application granted granted Critical
Publication of AU2014306451B2 publication Critical patent/AU2014306451B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
AU2014306451A 2013-08-16 2014-08-18 Substituted hydroxamic acid compounds Ceased AU2014306451B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361866823P 2013-08-16 2013-08-16
US61/866,823 2013-08-16
US201361867933P 2013-08-20 2013-08-20
US61/867,933 2013-08-20
PCT/US2014/051459 WO2015024010A2 (en) 2013-08-16 2014-08-18 Substituted hydroxamic acid compounds

Publications (2)

Publication Number Publication Date
AU2014306451A1 AU2014306451A1 (en) 2016-03-03
AU2014306451B2 true AU2014306451B2 (en) 2019-01-17

Family

ID=52468825

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014306451A Ceased AU2014306451B2 (en) 2013-08-16 2014-08-18 Substituted hydroxamic acid compounds

Country Status (6)

Country Link
US (1) US10647664B2 (enExample)
EP (1) EP3041354A4 (enExample)
JP (2) JP6458270B2 (enExample)
AU (1) AU2014306451B2 (enExample)
CA (1) CA2921427A1 (enExample)
WO (1) WO2015024010A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10647664B2 (en) * 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
EP3143007B1 (en) 2014-05-16 2018-07-11 Idorsia Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
WO2017083434A1 (en) 2015-11-09 2017-05-18 Forge Therapeutics, Inc. Pyrone based compounds for treating bacterial infections
WO2017083431A2 (en) 2015-11-09 2017-05-18 Forge Therapeutics, Inc. Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
EP3448375B1 (en) * 2016-04-25 2023-09-27 Duke University Benzoylglycine derivatives and methods of making and using same
WO2018115421A1 (en) * 2016-12-23 2018-06-28 Intervet International B.V. Compounds useful for treating a mannheimia haemolytica or histophilus somni infection
EP3621962A4 (en) 2017-05-10 2020-12-09 Forge Therapeutics, Inc. ANTIBACTERIAL COMPOUNDS
BR112020016270A2 (pt) * 2018-02-10 2020-12-15 Kbp Biosciences Co., Ltd. Composto atuando como antibióticos
CA3113226A1 (en) * 2018-09-20 2020-03-26 Forge Therapeutics, Inc. Antibacterial compounds
US12617767B2 (en) 2019-07-17 2026-05-05 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
WO2021195260A1 (en) 2020-03-25 2021-09-30 Forge Therapeutics, Inc. Lpxc inhibitor and methods of making
WO2022055880A1 (en) 2020-09-09 2022-03-17 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
CA3233328A1 (en) 2021-09-28 2023-04-06 Min Teng Lpxc inhibitors and uses thereof
US20260102415A1 (en) * 2022-10-05 2026-04-16 Duke University Compositions comprising prodrugs of hydroxamate-based compounds and methods of making and using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163496A1 (en) * 2003-01-08 2009-06-25 University Of Washington Antibacterial agents
WO2012031298A2 (en) * 2010-09-03 2012-03-08 Duke University Ethynylbenzene derivatives
WO2012143340A1 (en) * 2011-04-19 2012-10-26 F. Hoffmann-La Roche Ag 5-(phenyl/pyridinyl-ethinyl)-2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators
US20130072677A1 (en) * 2010-04-20 2013-03-21 Toyama Chemical Co., Ltd. Novel hydroxamic acid derivative

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014077A1 (en) 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5925659A (en) 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
JP2000344752A (ja) * 1999-04-01 2000-12-12 Sumitomo Pharmaceut Co Ltd 点眼剤
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
ATE510817T1 (de) * 2002-01-29 2011-06-15 Merck Serono Sa Substituierte methylenamidderivate als modulatoren von proteintyrosinphosphatasen (ptps)
BR0309671A (pt) 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
AU2003267991B2 (en) 2002-07-11 2009-10-08 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
US20050154022A1 (en) 2004-01-14 2005-07-14 H. Lundbeck A/S 4-aryl piperidines
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
AT502219B1 (de) 2005-08-04 2007-04-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von 5-substituierten tetrazolen
US7553864B2 (en) 2005-12-01 2009-06-30 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
JP2010502617A (ja) 2006-08-31 2010-01-28 シェーリング コーポレイション 抗菌物質として有用なヒダントイン誘導体
JP5227304B2 (ja) 2007-02-28 2013-07-03 大正製薬株式会社 新規なヒドロキサム酸誘導体
CA2934114A1 (en) 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
WO2009158369A1 (en) 2008-06-25 2009-12-30 Schering Corporation Synthesis and use of heterocyclic antibacterial agents
EP2315746A1 (en) 2008-08-04 2011-05-04 Schering Corporation Urea derivatives as antibacterial agents
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2011005355A1 (en) 2009-05-07 2011-01-13 Achaogen, Inc. Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
CA2774250C (en) * 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
PL2512474T3 (pl) 2009-12-16 2015-03-31 Pfizer N-przyłączone pochodne kwasu hydroksamowego użyteczne jako środki przeciwbakteryjne
WO2013049255A1 (en) * 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors
JP6006609B2 (ja) * 2011-10-19 2016-10-12 大正製薬株式会社 新規なヒドロキサム酸誘導体を含有する医薬
EP2847168A1 (en) * 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
LT2975022T (lt) * 2013-03-15 2019-07-25 Fujifilm Toyama Chemical Co., Ltd. Naujas hidroksamo rūgšties darinys arba jo druska
US10647664B2 (en) * 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163496A1 (en) * 2003-01-08 2009-06-25 University Of Washington Antibacterial agents
US20130072677A1 (en) * 2010-04-20 2013-03-21 Toyama Chemical Co., Ltd. Novel hydroxamic acid derivative
WO2012031298A2 (en) * 2010-09-03 2012-03-08 Duke University Ethynylbenzene derivatives
WO2012143340A1 (en) * 2011-04-19 2012-10-26 F. Hoffmann-La Roche Ag 5-(phenyl/pyridinyl-ethinyl)-2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1209455-90-2; STN Entry Date: 12 Mar 2010; Chemical Name: Benzamide, N-(1,1-dimethylethyl)-2-(2-phenylethynyl)- *
CAS Registry Number 1209455-91-3; STN Entry Date: 12 Mar 2010; Chemical Name: Benzamide, N-(1,1-dimethylethyl)-2-[2-(4-methoxyphenyl)ethynyl]- *
CAS Registry Number 1209455-92-4; STN Entry Date: 12 Mar 2010 Chemical Name: Benzamide, N-(1,1-dimethylethyl)-2-[2-[4-(trifluoromethyl)phenyl]ethynyl]- *
CAS Registry Number 1209455-93-5; STN Entry Date: 12 Mar 2010; Chemical Name: Benzamide, N-(1,1-dimethylethyl)-2-[2-(1-naphthalenyl)ethynyl]- *
MICHAEL R. HALE ET AL, "Exploring the UDP pocket of LpxC through amino acid analogs", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (20130401), vol. 23, no. 8, doi:10.1016/j.bmcl.2013.02.055, ISSN 0960-894X, pages 2362 - 2367 *

Also Published As

Publication number Publication date
CA2921427A1 (en) 2015-02-19
WO2015024010A3 (en) 2015-04-16
JP2019077688A (ja) 2019-05-23
WO2015024010A2 (en) 2015-02-19
EP3041354A4 (en) 2017-06-14
JP6458270B2 (ja) 2019-01-30
US20160221934A1 (en) 2016-08-04
JP2016535758A (ja) 2016-11-17
AU2014306451A1 (en) 2016-03-03
EP3041354A2 (en) 2016-07-13
US10647664B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
JP6458270B2 (ja) 置換されたヒドロキサム酸化合物
RU2745071C2 (ru) Лекарственный препарат для лечения гриппа, характеризующийся тем, что в нем объединены ингибитор кэп-зависимой эндонуклеазы и лекарственное средство против гриппа
RU2727962C1 (ru) Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство
RU2671847C2 (ru) Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона
JP4405602B2 (ja) ヒストン脱アセチル化酵素阻害剤
AU2019310508B2 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
RS64012B1 (sr) Derivati supstituisanog policikličnog piridona i njihov prolek
WO2012031298A2 (en) Ethynylbenzene derivatives
JPH11335375A (ja) ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
US9908851B2 (en) 2-piperidinyl substituted N,3-dihydroxybutanamides
Ahmed et al. 1, 2, 4-Triazolo-[1, 5-a] pyridine HIF prolylhydroxylase domain-1 (PHD-1) inhibitors with a novel monodentate binding interaction
US20220002291A1 (en) Proteolysis-targeting chimeras
WO2007149782A2 (en) Selective inhibitors for transferases
US11103511B2 (en) Substituted indolo[2,1-b]quinazolines as inhibitors of tryptophan dioxygenase and indoleamine 2,3-dioxygenase 1
MX2010013842A (es) Naftiridinonas como inhibidores de aurora cinasa.
Moghimi et al. Design and synthesis of novel pyridazine N-aryl acetamides: In-vitro evaluation of α-glucosidase inhibition, docking, and kinetic studies
JP6859358B2 (ja) テトラヒドロインダゾール及びその医学的使用
WO2015024011A2 (en) Antibacterial compounds
ES2961564T3 (es) Derivados de benzoilglicina y métodos de preparación y uso de los mismos
CA3152306A1 (en) Selective hdac6 degraders and methods of use thereof
CN115745979A (zh) 一种蛋白靶向降解化合物及其用途
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
ES2782357T3 (es) Inhibidores de IRE 1 alfa
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
HK40104425A (en) Benzoylglycine derivatives and methods of making and using same

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UNIVERSITY OF NORTH CAROLINA

Free format text: FORMER NAME(S): DUKE UNIVERSITY

Owner name: DUKE UNIVERSITY

Free format text: FORMER NAME(S): DUKE UNIVERSITY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired